Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Shares Issued (2020 - 2025)

Lyell Immunopharma's Shares Issued history spans 6 years, with the latest figure at $184000.0 for Q2 2025.

  • For Q2 2025, Shares Issued fell 73.97% year-over-year to $184000.0; the TTM value through Sep 2025 reached $622000.0, down 35.28%, while the annual FY2024 figure was $1.2 million, 307.84% up from the prior year.
  • Shares Issued for Q2 2025 was $184000.0 at Lyell Immunopharma, down from $438000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $392.0 million in Q2 2021 and bottomed at -$3.2 million in Q3 2022.
  • The 5-year median for Shares Issued is $572500.0 (2024), against an average of $28.8 million.
  • The largest annual shift saw Shares Issued plummeted 3128.57% in 2021 before it skyrocketed 190.07% in 2024.
  • A 5-year view of Shares Issued shows it stood at -$1.1 million in 2021, then soared by 919.81% to $8.7 million in 2022, then plummeted by 98.26% to $151000.0 in 2023, then soared by 190.07% to $438000.0 in 2024, then crashed by 57.99% to $184000.0 in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Shares Issued are $184000.0 (Q2 2025), $438000.0 (Q4 2024), and $707000.0 (Q2 2024).